TP53 and breast carcinoma: Cytotoxicity studies conducted against the human colon carcinoma cell lines HCT-116wt, its p53 knockout mutant HCT-116−/−, and the mdr human breast cancer cell line MCF-7topo, show low micromolar and even nanomolar activity.